Huntington’s Disease and Neurodegeneration

Heinz, Annika; Nabariya, Deepti Kailash; Krauß, Sybille

doi:10.1007/978-3-031-15080-7_226

Cited by 2 publications

(1 citation statement)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gradually, the aggregates may sequester ubiquitin, proteasome subunits, chaperones, transcriptional factors, or wild-type alleles which induce neurotoxic effects, leading to an impairment in the ubiquitin-proteasome system. Indeed, the aggregates show abnormal axonal transport of the autophagosome-lysosome system, contributing to inefficient autophagosome-lysosome fusion and decreased degradation of the aggregates [45].…”

Section: Huntington's Diseasementioning

confidence: 99%

Small Extracellular Vesicles’ miRNAs: Biomarkers and Therapeutics for Neurodegenerative Diseases

et al. 2023

View full text Add to dashboard Cite

Neurodegenerative diseases are critical in the healthcare system as patients suffer from progressive diseases despite currently available drug management. Indeed, the growing ageing population will burden the country’s healthcare system and the caretakers. Thus, there is a need for new management that could stop or reverse the progression of neurodegenerative diseases. Stem cells possess a remarkable regenerative potential that has long been investigated to resolve these issues. Some breakthroughs have been achieved thus far to replace the damaged brain cells; however, the procedure’s invasiveness has prompted scientists to investigate using stem-cell small extracellular vesicles (sEVs) as a non-invasive cell-free therapy to address the limitations of cell therapy. With the advancement of technology to understand the molecular changes of neurodegenerative diseases, efforts have been made to enrich stem cells’ sEVs with miRNAs to increase the therapeutic efficacy of the sEVs. In this article, the pathophysiology of various neurodegenerative diseases is highlighted. The role of miRNAs from sEVs as biomarkers and treatments is also discussed. Lastly, the applications and delivery of stem cells and their miRNA-enriched sEVs for treating neurodegenerative diseases are emphasised and reviewed.

show abstract

Section: Huntington's Diseasementioning

confidence: 99%